|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex.
|
31754215 |
2020 |
|
Psychotic Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, we observed no P50 suppression deficit in those EOP patients diagnosed with schizophrenia (N = 39).
|
31649298 |
2020 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we observed no P50 suppression deficit in those EOP patients diagnosed with schizophrenia (N = 39).
|
31649298 |
2020 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Psychopathology of SCZ was rated by the positive and negative syndrome scale (PANSS), while cognitive function and P50 inhibition of subjects were assessed by the MATRICS Consensus Cognitive Battery (MCCB) and the electroencephalography system.
|
31780341 |
2020 |
|
Nonorganic psychosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we observed no P50 suppression deficit in those EOP patients diagnosed with schizophrenia (N = 39).
|
31649298 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex.
|
31754215 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The classical NF-κB transcription factor (RelA:p50) and the tumor suppressor Sef axis constitute a negative regulatory loop in which Sef, a target of NF-κB/RelA:p50, fine-tunes NF-κB/RelA:p50 transcriptional-activation in response to inflammatory stimuli trough binding to p50.
|
30862497 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proposed sensing system also has high selectivity and it can be used to interrogate the presence of NF-κB p50 in tumor cell extracts, demonstrating its potential for disease diagnosis and gene transcription-related studies.
|
31408824 |
2019 |
|
Psychotic Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, brain connectivity (HC < HR < UHR < FESZ) in the gamma band of P50 components was increasingly enhanced in accordance with the level of psychosis risks.
|
31111773 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings provide insight into the mechanisms of P50 suppression in schizophrenia and could potentially improve the performance of early identification and diagnosis of schizophrenia for the earliest intervention.
|
31803031 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CHRNA7 gene encoding the α7 nicotinic acetylcholine receptor (nAChR) has repeatedly been linked with schizophrenia and the P50 sensory gating deficit.
|
30974230 |
2019 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PERG results showed a significant increase of the P50 implicit time in schizophrenia patients compared with controls (t(55) = 2.1, p < .05, d = 0.55) and a significant increase of the N95 implicit time in schizophrenia patients compared with controls (t(55) = 4.2; p < .001, d = 0.66).
|
31353068 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated with alpha 7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction and shown to be improved with nicotine and α7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment.
|
30920339 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Auditory P50 gating and hippocampal volume were measured in 16 male and 15 female patients with schizophrenia.
|
30862179 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined two candidate mechanisms of AVH in patients with BPD, suggested to underlie sensory processing systems that contribute to psychotic symptoms in patients with schizophrenia; sensory gating (P50 ratio and P50 difference) and change detection (mismatch negativity; MMN).
|
31536946 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following reports of SG improvements in low P50 suppressing SCZ patients and healthy participants with the α7 agonist, CDP-choline, this pilot study examined the combined modulatory effect of CDP-choline (500 mg) and galantamine (16 mg), a nAChR positive allosteric modulator and acetylcholinesterase inhibitor, on SG to speech stimuli in twenty-four SCZ patients in a randomized, double-blind and placebo-controlled design.
|
30790597 |
2019 |
|
Nonorganic psychosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, brain connectivity (HC < HR < UHR < FESZ) in the gamma band of P50 components was increasingly enhanced in accordance with the level of psychosis risks.
|
31111773 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using genetic models, we linked the PDE4-regulated modulation of P85 activation to the oncogenic kinase SYK.<b>Conclusions:</b> These data demonstrate that roflumilast and idelalisib suppress PI3K by distinct mechanisms, explaining the basis for their synergism, and suggest that the repurposing of PDE4 inhibitors to treat BCR-dependent malignancies is warranted.<i></i>.
|
29246942 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings point to p50 involvement in colorectal cancer development, through its engagement in the protumor activation of macrophages, and identify a candidate for prognostic and target therapeutic intervention.<i>Cancer </i>.
|
29588321 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The levels of NF-κB p50 and NF-κB p65 play a role in thyroid carcinoma malignancy in vivo.
|
30014762 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
American Indians (N = 636) were recruited from two different tribal populations (NP and SW) as part of a study conducted as part of the Collaborative to Improve Native Cancer Outcomes P50 project.
|
28549179 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, according to ReMARK guidelines for reporting prognostic biomarkers in cancer, it was found that a high expression of ARHGEF7 was significantly correlated with lymph node, mesenteric and distant metastasis.
|
30132516 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth.
|
29588411 |
2018 |